Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 26;10(17):3829.
doi: 10.3390/jcm10173829.

Vascular Resection for Intrahepatic Cholangiocarcinoma: Current Considerations

Affiliations
Review

Vascular Resection for Intrahepatic Cholangiocarcinoma: Current Considerations

Ruslan Alikhanov et al. J Clin Med. .

Abstract

Intrahepatic cholangiocarcinoma (iCCA) accounts for approximately 10% of all primary liver cancers. Surgery is the only potentially curative treatment, even in cases of macrovascular invasion. Since resection offers the only curative chance, even extended liver resection combined with complex vascular or biliary reconstruction of the surrounding organs seems justified to achieve complete tumour removal. In selected cases, the major vascular resection is the only change to try getting the cure. The best results are achieved by the referral centre with a wide experience in complex liver surgery, such as ALPPS procedure, IVC resection, and ante-situ and ex-situ resections. However, despite aggressive surgery, tumour recurrence occurs frequently and long-term oncological results are very poor. This suggests that significant progress in prognosis cannot be expected by surgery alone. Instead, multimodal treatment including neoadjuvant chemotherapy, radiotherapy, and subsequent adjuvant treatment for iCCA seem to be necessary to improve results.

Keywords: cholangiocarcinoma; intrahepatic cholangiocarcinoma; liver resection; survival; vascular resection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Wu L., Tsilimigras D.I., Paredes A.Z., Mehta R., Hyer J.M., Merath K., Sahara K., Bagante F., Beal E., Shen F., et al. Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival. World J. Surg. 2019;43:1777–1787. doi: 10.1007/s00268-019-04966-4. - DOI - PubMed
    1. Altekruse S.F., Petrick J.L., Rolin A.I., Cuccinelli J.E., Zou Z., Tatalovich Z., McGlynn K.A. Geographic Variation of Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, and Hepatocellular Carcinoma in the United States. PLoS ONE. 2015;10:e0120574. doi: 10.1371/journal.pone.0120574. - DOI - PMC - PubMed
    1. Van Dyke A.L., Shiels M.S., Jones G., Pfeiffer R.M., Petrick J.L., Beebe--Dimmer J.L., Koshiol J. Biliary tract cancer incidence and trends in the United States by demographic group, 1999–2013. Cancer. 2019;125:1489–1498. doi: 10.1002/cncr.31942. - DOI - PMC - PubMed
    1. Bertuccio P., Bosetti C., Levi F., Decarli A., Negri E., La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann. Oncol. 2013;24:1667–1674. doi: 10.1093/annonc/mds652. - DOI - PubMed
    1. Endo I., Gonen M., Yopp A.C., Dalal K.M., Zhou Q., Klimstra D., D’Angelica M., DeMatteo R.P., Fong Y., Schwartz L., et al. Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. Ann. Surg. 2008;248:84–96. doi: 10.1097/SLA.0b013e318176c4d3. - DOI - PubMed

LinkOut - more resources